Celcuity Publishes Presentation on Gedatolisib in Advanced Breast Cancer

• Celcuity published a medical research presentation comparing gedatolisib regimens in previously treated PIK3CA wild-type HR-positive, HER2-negative advanced breast cancer.
• The gedatolisib triplet significantly improved progression-free survival versus all non-gedatolisib regimens except ribociclib with fulvestrant in the eight-study network meta-analysis.
• Six-month progression-free survival favored the triplet by 38 percentage points versus capivasertib with fulvestrant; the advantage versus imlunestrant with abemaciclib was 20 points.
• The gedatolisib doublet showed a statistically significant 31-percentage-point improvement in six-month progression-free survival versus capivasertib with fulvestrant.
• Findings relied on indirect treatment comparisons, with cross-trial differences and assumptions limiting interpretation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celcuity Inc. published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.